480 Comparative Outcomes of Bone-Modifying Agents and Multikinase Inhibitors in Chordoma: A Real-World Cohort Analysis

View at publisher Summarise with VIRAT
Authors: Kamal Shaik, Spencer T. Rasmussen, Rudy J. Rahme, Michael J. Karsy
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Chordomas are rare, locally aggressive tumors of notochordal origin, commonly affecting the sacrum, spine, and skull base. These tumors pose significant management challenges due to their propensity for local recurrence, osseous metastasis, and the limited efficacy of systemic therapies. Bone-modifying agents and multikinase inhibitors (MKIs) have been used in other bone-involved malignancies, but their comparative effectiveness in chordoma remains poorly defined. METHODS: A retrospective cohort study was conducted using the TriNetX Global Collaborative Network, identifying 2024 patients of all ages who were diagnosed with chordoma and received either zoledronic acid, denosumab, or MKIs (lenvatinib, sorafenib, cabozantinib). Patients with chordoma were identified using ICD-10-CM codes C41.0, C41.2, and C41.4, and treatment cohorts were defined by RxNorm codes. Propensity score matching was performed for age, sex, race, and ethnicity. Outcomes assessed five years post-diagnosis included all-cause mortality (primary), spinal cord compression, osteonecrosis of the jaw, and pathologic fracture. Risk ratios with 95% confidence intervals were calculated. RESULTS: Zoledronic acid and MKIs resulted in increased five-year mortality in chordoma compared with denosumab. Specifically, patients who received zoledronic acid had 1.223 times greater risk of mortality (95% CI: 1.064-1.406; p < 0.005). Likewise, patients who received denosumab had 0.764 times less risk of mortality (95% CI: 0.596-0.98; p < 0.05) compared to the MKI cohort. However, patients who received zoledronic acid had a significantly lower risk of developing osteonecrosis compared to the denosumab cohort. There was no significant risk of pathologic fracture, or spinal cord compression between cohorts. CONCLUSIONS: Denosumab was associated with improved five-year survival in chordoma patients compared to zoledronic acid and MKIs. These findings provide preliminary evidence supporting denosumab as a potential adjunct in chordoma management and highlight the need for further clinical trials.

Fields of Study & Subjects

Bone Tumor Diagnosis and Treatments Bone health and treatments Sarcoma Diagnosis and Treatment

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
141–141
Publication date
26 March 2026
Language
EN